PA
SAGE

Profund Advisors’s Sage Therapeutics SAGE Stock Holding History

Profund Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29,348
Closed -$212K – 1176
2024
Q3 		$212K Buy
29,348
+6,389
+28% +$58.5K 0.01% 1023
2024
Q2 		$249K Sell
22,959
-37,624
-62% -$482K 0.01% 840
2024
Q1 		$1.14M Buy
60,583
+10,870
+22% +$251K 0.04% 327
2023
Q4 		$1.08M Sell
49,713
-19,042
-28% -$377K 0.05% 310
2023
Q3 		$1.41M Buy
68,755
+43,076
+168% +$1.24M 0.08% 204
2023
Q2 		$1.21M Sell
25,679
-5,465
-18% -$272K 0.06% 276
2023
Q1 		$1.31M Buy
+31,144
New +$1.34M 0.08% 225
2020
Q3 		– Sell
-11,507
Closed -$478K – 1005
2020
Q2 		$478K Buy
11,507
+1,766
+18% +$64.1K 0.03% 412
2020
Q1 		$280K Sell
9,741
-3,547
-27% -$205K 0.02% 516
2019
Q4 		$959K Buy
13,288
+1,401
+12% +$172K 0.04% 360
2019
Q3 		$1.67M Sell
11,887
-713
-6% -$119K 0.08% 226
2019
Q2 		$2.31M Sell
12,600
-1,393
-10% -$238K 0.11% 171
2019
Q1 		$2.23M Buy
13,993
+1,127
+9% +$163K 0.11% 176
2018
Q4 		$1.23M Sell
12,866
-3,101
-19% -$355K 0.08% 244
2018
Q3 		$2.25M Buy
+15,967
New +$2.46M 0.09% 201

Other funds holding SAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Profund Advisors's SAGE Position: Q4 2024 in Review

Profund Advisors sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 29,348 shares — an estimated $212K sold.

Profund Advisors first reported a position in SAGE in Q3 2018 and held it in 15 quarters. The position peaked at $2.31M in Q2 2019. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

  • Profund Advisors reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Profund Advisors sold 29,348 Sage Therapeutics shares in Q4 2024, an estimated $212K.
  • Profund Advisors first reported a position in Sage Therapeutics in Q3 2018 and held it in 15 quarters.
  • Profund Advisors's Sage Therapeutics position peaked at $2.31M in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Profund Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.